Enocyanin Synergistically Enhances Sorafenib Sensitivity in Hepatocellular Carcinoma via Ferroptosis Induction Associated with p62/Keap1/Nrf2/HO-1 Pathway Inhibition
Current Issues in Molecular Biology · 28.03.2026 · 48 (4) · 357
DOI: 10.3390/cimb48040357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 28.03.2026. Verfasst von Mengting Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ningxia Natural Science Foundation, Ningxia Medical University Project.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) poses a critical threat to global health because of the scarcity of effective therapeutic approaches. Sorafenib, a first-line treatment for advanced HCC, often faces efficacy limitations due to acquired resistance. Therefore, it is urgent to explore novel and effective anti-cancer drugs and combination therapies. This study explored the anti-HCC potential of Enocyanin (Eno), a natural anthocyanin-rich extract derived from grapes, either alone or combined with sorafenib. Our findings indicated that 100 μg/mL Eno remarkably suppressed the proliferation, invasion and migration of HepG2 cells, which was related to the induction of ferroptosis characterized by increased intracellular Fe2+, lipid peroxidation (LPO) and Acyl-CoA synthetase long chain family member 4 (ACSL4) levels, coupled with decreased glutathione (GSH) and glutathione peroxidase 4 (GPX4). Mechanistically, Eno promoted ferroptosis which was associated with inhibition of the p62/Keap1/Nrf2/HO-1 signaling pathway. Notably, Eno (100 μg/mL) combined with sorafenib (2 μM) had a synergistic anti-tumor effect (Q = 1.47), which further enhanced the inhibition of HepG2 cell growth and metastasis, aggravated ferroptosis, and more strongly suppressed the p62/Keap1/Nrf2/HO-1 axis. In the C57BL/6 mouse subcutaneous HCC transplantation model, the combination of Eno and sorafenib showed a stronger inhibitory effect on tumor growth, reaching a 70% inhibition rate, compared to 33% with Eno alone and 55% with sorafenib alone. In summary, this study demonstrates that Eno may be a novel inducer of ferroptosis, and it has the potential to be used in the treatment of hepatocellular carcinoma. It also provides a potential combined treatment strategy for enhancing the sensitivity of sorafenib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China.
- School of Inspection, Ningxia Medical University, Yinchuan 750004, China.
- The First Clinical College, Ningxia Medical University, Yinchuan 750004, China.
- School of Public Health, Ningxia Medical University, Yinchuan 750004, China.
ORCID-Profile: Changcai Bai
Förderung
- National Natural Science Foundation of China
- Ningxia Natural Science Foundation
- Ningxia Medical University Project
Zitieren
APA
Tian, M., Ma, J., Wei, T., Meng, K., Xia, Y., Zong, X., Bai, C., & Wang, Z. (2026). Enocyanin Synergistically Enhances Sorafenib Sensitivity in Hepatocellular Carcinoma via Ferroptosis Induction Associated with p62/Keap1/Nrf2/HO-1 Pathway Inhibition. Current Issues in Molecular Biology, 48(4), 357. https://doi.org/10.3390/cimb48040357
Vancouver
Tian M, Ma J, Wei T, Meng K, Xia Y, Zong X, et al. Enocyanin Synergistically Enhances Sorafenib Sensitivity in Hepatocellular Carcinoma via Ferroptosis Induction Associated with p62/Keap1/Nrf2/HO-1 Pathway Inhibition. Current Issues in Molecular Biology. 2026;48(4):357. doi:10.3390/cimb48040357
BibTeX
@article{Tian2026,
author = {Tian, Mengting and Ma, Jing and Wei, Tingting and Meng, Kunqi and Xia, Yingmeng and Zong, Xue and Bai, Changcai and Wang, Zhisheng},
title = {Enocyanin Synergistically Enhances Sorafenib Sensitivity in Hepatocellular Carcinoma via Ferroptosis Induction Associated with p62/Keap1/Nrf2/HO-1 Pathway Inhibition},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {4},
pages = {357},
doi = {10.3390/cimb48040357}
}
EUVIMED